Cost–utility analysis of once-daily versus twice-daily inhaled corticosteroid dosing for maintenance treatment of asthma in pediatric patients

Vista sencilla de ítem
dc.contributor.authorRodriguez-Martinez, Carlos E.
dc.contributor.authorSossa-Briceño, Monica P.
dc.contributor.authorCastro-Rodriguez, Jose A.
dc.date.accessioned2020-08-06T16:56:35Z
dc.date.available2020-08-06T16:56:35Z
dc.description.abstractenglishObjective: Suboptimal adherence to inhaled corticosteroids (ICs) is an important cause of poor asthma control in pediatric patients. Among the factors that can be most easily changed for enhancing adherence to ICs is a reduction in the dosing frequency, from twice-daily dosing to once-daily dosing. However, no previous studies have reported an economic evaluation comparing once-daily versus twice-daily IC dosing for pediatric asthma. The aim of this study was to compare the cost-effectiveness of once-daily versus twice-daily IC dosing for maintenance treatment of asthma in pediatric patients. Methods: A Markov-type model was developed in order to estimate costs and health outcomes of a simulated cohort of pediatric patients with persistent asthma treated over a 12-month period. Effectiveness parameters were obtained from a systematic review of the literature. Cost data were obtained from official databases provided by the Colombian Ministry of Health. The main outcome was the variable “quality-adjusted life-years” (QALYs). Results: For the base-case analysis, the model showed that compared with twice-daily dosing, once-daily dosing strategy involved lower costs (US$1529.3 versus $1709.1 average cost per patient over 12 months) and the greatest gain in QALYs (0.8284 versus 0.8084 QALYs on average per patient over 12 months), resulting in once-daily dosing strategy being considered dominant. Conclusions: This study shows that compared with twice-daily dosing, once-daily IC dosing for treating pediatric patients with persistent asthma is the dominant strategy because it involves a greater gain in QALYs at lower total treatment cost.eng
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.3109/02770903.2015.1116087
dc.identifier.instnameinstname:Universidad El Bosquespa
dc.identifier.issn1532-4303
dc.identifier.reponamereponame:Repositorio Institucional Universidad El Bosquespa
dc.identifier.repourlhttps://repositorio.unbosque.edu.co
dc.identifier.urihttps://hdl.handle.net/20.500.12495/3701
dc.language.isoeng
dc.publisherTaylor and Francisspa
dc.publisher.journalThe Journal of Asthmaspa
dc.relation.ispartofseriesThe Journal of Asthma, 1532-4303, Vol. 53, Nro. 5, 2016, p. 538–545spa
dc.relation.urihttps://www.tandfonline.com/doi/full/10.3109/02770903.2015.1116087
dc.rights.accessrightshttps://purl.org/coar/access_right/c_abf2
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.accessrightsAcceso abierto
dc.rights.creativecommons2016-01-19
dc.rights.localAcceso abiertospa
dc.subject.keywordsAdherencespa
dc.subject.keywordsAsthmaspa
dc.subject.keywordsCost-effectivenessspa
dc.subject.keywordsInhaled corticosteroidsspa
dc.subject.keywordsQuality-adjusted life yearsspa
dc.titleCost–utility analysis of once-daily versus twice-daily inhaled corticosteroid dosing for maintenance treatment of asthma in pediatric patientsspa
dc.title.translatedCost–utility analysis of once-daily versus twice-daily inhaled corticosteroid dosing for maintenance treatment of asthma in pediatric patientsspa
dc.type.coarhttps://purl.org/coar/resource_type/c_6501
dc.type.driverinfo:eu-repo/semantics/article
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.type.localArtículo de revista

Archivos

Bloque original
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
Rodriguez-Martinez, Carlos E..pdf
Tamaño:
938.35 KB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
1.71 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos